Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 2, 2009, Pages 192-195

  Spagnuolo, Vincenzo ^a   Gianotti, Nicola ^a   Seminari, Elena ^a   Galli, Laura ^a   Fusetti, Giuliana ^a   Salpietro, Stefania ^a   Lazzarin, Adriano ^a,b   Castagna, Antonella ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Daranavir r; Resistance; Sequencing; Stanford mutation score; Tipranavir r

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR; ENFUVIRTIDE; ETRAVIRINE; MARAVIROC; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR; VIRUS RNA; PROTEINASE; PYRIDINE DERIVATIVE; PYRONE DERIVATIVE; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RNA DIRECTED DNA POLYMERASE; SULFONAMIDE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; R FACTOR; SCORING SYSTEM; VIRUS MUTATION; ANTIVIRAL RESISTANCE; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; TREATMENT FAILURE; VIROLOGY;

DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION; PYRIDINES; PYRONES; SULFONAMIDES; TREATMENT FAILURE;

EID: 60749098495     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31819367fc     Document Type: Article

References (11)

1. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368:466-475.
2. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169-1178.
3. Shirasaka T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA. 1995;92:2398-2402.
4. Schmit JC, Cogniaux J, Hermans P, et al. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis. 1996;174:962-968.
5. Iversen AK, Shafer RW, Wehrly K, et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol. 1996;70:1086-1090.
6. Zaccarelli M, Perno CF, Forbici F, et al. Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy. Clin Infect Dis. 2004;38:433-437.
7. Picchio G, Staes M, Van Craenenbroeck, et al. HIV-1 susceptibility to TMC114 among routine clinical samples with different levels of protease inhibitor susceptibility using linear regression model-based fold change predictions. In: Programme and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006. Abstract H-999.
8. Lefebvre E, de Bethune M, De Meyer, et al. Impact of use of TPV, LPV, and, (f)APV at screening on TMC114/r virologie response in treatment-experienced patients in POWER 1, 2, and 3. In: Programme and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006. Abstract H-1387.
9. Baxter JD, Schapiro JM, Boucher CA, et al. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologie response to the protease inhibitor tipranavir. J Virol. 2006;80:10794-10801.
10. De Meyer S, Dierynck I, Lathouwers E, et al. Identification of mutations predictive of a diminished response to darunavir/ritonavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and 2. Presented at: Program and abstracts of the 6th European HIV Drug Resistance Workshop; March 26-28, 2008; Budapest, Hungary. Abstract 54.
11. Scherer J, Boucher CA, Baxter JD, et al. Improving the prediction of virological response to tipranavir: the development of a tipranavir weighted score. Presented at: 11th European AIDS Conference; October 24-27, 2007; Madrid, Spain. Poster P3.4/07.